基因總覽
C3(complement C3)是蛋白質編碼基因,其產物是補體系統的前驅蛋白,提供非酵素性成分,參與 classical、alternative、lectin 與 GZMK 補體途徑。這些途徑由多種蛋白質接續作用,並與吞噬、病原體分解及支持適應性免疫的訊號相關。C3的產物可經切割形成具有不同作用的分子片段;其中包括補體途徑中的成分,以及與發炎反應或脂肪細胞代謝有關的產物。其蛋白質序列含訊號區、Anaphylatoxin-like domain、NTR domain及一段被註記為無序的區域。
基因異名與舊稱
異名取自 HGNC,可能包含歷史名稱;蛋白質名稱以 UniProt 註解為準。
染色體位置與基因結構
查看實際轉錄本與 exon 註解
| Transcript | Genomic coordinates | Exons |
|---|---|---|
| ENST00000245907 ★ | 6,677,704–6,720,650 | 41 |
| ENST00000695653 | 6,677,704–6,707,383 | 25 |
| ENST00000879543 | 6,677,704–6,720,683 | 41 |
| ENST00000879544 | 6,677,704–6,720,683 | 40 |
| ENST00000879546 | 6,677,704–6,720,683 | 41 |
| ENST00000952696 | 6,677,704–6,720,683 | 42 |
| ENST00000993982 | 6,677,704–6,720,683 | 41 |
| ENST00001034150 | 6,677,704–6,720,683 | 41 |
| ENST00001137464 | 6,677,704–6,720,683 | 41 |
| ENST00000879545 | 6,677,836–6,720,683 | 41 |
| ENST00000695654 | 6,677,847–6,713,315 | 32 |
| ENST00000602229 | 6,677,864–6,679,201 | 3 |
顯示 12/21 個蛋白質編碼轉錄本;canonical 優先。
帶型與著絲點依 Ensembl 座標繪製;核染色體長度以 GRCh38 第 1 號染色體為共同尺度。黃色標記表示本基因位置,細小區間加粗以利辨識;實際基因長度與 exon 見下方資料。
分子功能與生物學過程
C3是多條補體途徑共同使用的前驅物。經C3 convertase切割後,C3b可透過具反應性的硫酯鍵共價附著於病原體表面,也可連接細胞表面醣類或免疫聚集物。這種標記使抗原表面容易被辨識並移除,構成調理作用的一環。C3b也參與形成C5 convertase:在相關補體途徑中,它與C4b協同募集絲胺酸蛋白酶C2b;在 alternative pathway 中則募集CFB。形成的轉化酶可切割並活化補體級聯的下一成分C5。
另一種切割產物C3a是局部發炎的介質。它與受體C3AR1結合並啟動G蛋白偶聯受體訊號,同時促進受體磷酸化,以及由ARRB2介導的內化與胞吞。C3a可刺激肥大細胞及嗜鹼性白血球釋放細胞激素、趨化因子與組織胺,促進發炎反應;也能吸引巨噬細胞與嗜中性球移向發炎組織,協助透過吞噬及產生活性氧化物等方式中和發炎誘因。另有資料指出C3具有吸引嗜中性球的作用,尤其涉及慢性發炎。
C3的切割產物亦有代謝相關作用。ASP被描述為脂肪生成激素,可促進脂肪細胞的三酸甘油酯合成與葡萄糖運輸,參與脂肪儲存及餐後三酸甘油酯清除。其促進三酸甘油酯合成的作用似乎涉及PLC、MAPK與AKT訊號途徑;ASP與受體C5AR2結合後,也會促進受體訊號、磷酸化,以及ARRB2介導的內化與胞吞。與C3a不同,ASP未顯示促發炎活性。
Promoter 與基因調控
>C3 ENST00000245907 GRCh38 chr19:6720550-6721650 strand=-1 5′→3′ 相對 TSS:-1000 到 +100 bp;1101 bp 依轉錄本 TSS 擷取的基因組序列;TSS = 0,兩端包含,未驗證為 promoter AATTTAGCCTGAGTGACAGAATGAAAAAAAAATTTTTTTAAAGGAAAACACAAAAAGAATATGCTGTCAA CAGGGATGGGAGGAAGACCACCTTTACTGCTATACACATTTGTACCTTTTAGATGTTGATCAATATGAAT ATATTATACACACAGACACACACACAGACACACACACACACACAAACAATACAATTTAATATCCTAAGAG GATATTGACATTAGACAGGTACAAAAGCTCTAGAAATGAGGACTTTCCTCAGTGATGACTTTTTTCACCA CCAAAGTCACTCAGGCATCCTGACAAGGGTAAGTGAGGGGAGCCTCCTTGGAAAATAAACTCACTTGGAT AGTGAACTCCTGCACATACCTCAAAGCCCATCTGAAATGTCCCCTCCTACAGGAAGTTTTCCCTGACCCT CCAAGAAGCAGAGTTCTATTTCACTGGGGAAAACATTTCTTCTTCTTCTTTTTTTTCCCTGCCCTGCACA TGAGCTAGAAAACATTTCATGAAACTGGGAGTTTCTGTGCTGGGCTCTGTCCCTCCCCCATTCTACTTCC CCTCCCTCAGCATGGAAGCCTCTGGAAGTGGGGCTCTGACTCCCAGCCTACAGAGAGATTCCTAGGAAGT GTTCGACTGATAAACGCATGGCCAAAAGTGAACTGGGGATGAGGTCCAAGACATCTGCGGTGGGGGGTTC TCCAGACCTTAGTGTTCTTCCACTACAAAGTGGGTCCAACAGAGAAAGGTCTGTGTTCACCAGGTGGCCC TGACCCTGGGAGAGTCCAGGGCAGGGTGCAGCTGCATTCATGCTGCTGGGGAACATGCCCTCAGGTTACT CACCCCATGGACATGTTGGCCCCAGGGACTGAAAAGCTTAGGAAATGGTATTGAGAAATCTGGGGCAGCC CCAAAAGGGGAGAGGCCATGGGGAGAAGGGGGGGCTGAGTGGGGGAAAGGCAGGAGCCAGATAAAAAGCC AGCTCCAGCAGGCGCTGCTCACTCCTCCCCATCCTCTCCCTCTGTCCCTCTGTCCCTCTGACCCTGCACT GTCCCAGCACCATGGGACCCACCTCAGGTCCCAGCCTGCTGCTCCTGCTAC
EPDnew 實驗支持 promoter/TSS · 2 筆
| EPDnew ID | TSS(1-based) | 股向 | 來源顯示區間 |
|---|---|---|---|
| C3_1 ↗ | 19:6,720,650 | 負股 | 6,720,640–6,720,699 |
| C3_2 ↗ | 19:6,730,592 | 負股 | 6,730,582–6,730,641 |
EPDnew human v006 · UCSC hg38,GRCh38/hg38,透過 UCSC 取得。TSS 具有 CAGE/RAMPAGE 等實驗資料支持;任意擷取的上下游區間仍需另行判讀調控功能,不能視為整段皆經功能驗證。
EPD 封存狀態 ↗ · UCSC 資料說明 ↗ · EPD team, SIB Swiss Institute of Bioinformatics; UCSC Genome Browser · CC BY 4.0
查看已取得的調控/motif 註解
ENSR19_53KMRB · CTCF_binding_site · 6717223–6717244 · regulatory
ENSR19_94MZQ · enhancer · 6717436–6717731 · regulatory
ENSR19_94MZS · promoter · 6717732–6718061 · regulatory
ENSR19_B3C2C · promoter · 6720625–6721140 · regulatory
ENSR19_87C42 · enhancer · 6721853–6722084 · regulatory
ENSR19_94N3D · enhancer · 6723114–6723505 · regulatory
ENSR19_87C56 · enhancer · 6723806–6724039 · regulatory
· motif · 6717225–6717241 · motif
· motif · 6718635–6718645 · motif
· motif · 6718651–6718661 · motif
· motif · 6718684–6718694 · motif
· motif · 6718702–6718712 · motif
· motif · 6718779–6718789 · motif
· motif · 6718875–6718885 · motif
· motif · 6718926–6718936 · motif
· motif · 6718977–6718987 · motif
· motif · 6718981–6718991 · motif
· motif · 6718983–6718993 · motif
· motif · 6719133–6719143 · motif
· motif · 6719155–6719165 · motif
· motif · 6719161–6719171 · motif
· motif · 6719238–6719251 · motif
· motif · 6721102–6721112 · motif
· motif · 6721852–6721874 · motif
· motif · 6721852–6721874 · motif
· motif · 6721864–6721876 · motif
· motif · 6721910–6721921 · motif
· motif · 6722007–6722020 · motif
· motif · 6722418–6722433 · motif
· motif · 6723226–6723236 · motif
· motif · 6723343–6723353 · motif
· motif · 6723962–6723975 · motif
· motif · 6725613–6725628 · motif
· motif · 6725615–6725628 · motif
蛋白質結構域與序列
參考蛋白質長度:1663 aa
C3蛋白質長1,663個胺基酸,含有位於第1至22位的訊號區、第693至728位的Anaphylatoxin-like domain,以及第1,518至1,661位的NTR domain。第954至973位被註記為無序區;第1,634至1,659位則有與CFP/properdin互作的區域註解。
蛋白質三維結構
細胞內定位
C3以分泌形式存在。 經切割形成的C3b可共價附著於病原體表面:其內部硫酯鍵會與標的表面的醣類抗原反應,形成醯胺鍵或酯鍵。 C3a anaphylatoxin亦有分泌定位註記。
深綠色圓點:來源記載的蛋白質定位;數量不表示含量。
細胞外定位:圓點散佈於細胞周圍,與細胞膜保持距離。
未繪示構造:Cell surface。這些構造未在通用細胞圖中標點,仍保留來源定位名稱。
動物細胞結構示意;器官大小與數量不按比例。點選細胞構造可查看定位註解。
交互作用與訊號網絡
拖曳節點後放開可帶動位置變化;點選夥伴查看證據。位置與連線長度不代表結合強度,圖中未推定夥伴彼此之間的關係。
更多交互作用夥伴 · 已取得 16 個夥伴
- AGR2O95994 · UniProt INTERACTION · 3 experiments
- CACNA1CQ13936 · UniProt INTERACTION · 2 experiments
- CD46P15529 · UniProt INTERACTION · 2 experiments
- CFBP00751 · UniProt INTERACTION · 3 experiments
- CFHP08603 · UniProt INTERACTION · 6 experiments · 3 筆來源紀錄
- CFHR1Q03591 · UniProt INTERACTION · 2 experiments
- CFHR4Q92496-1 · UniProt INTERACTION · 5 experiments · 2 筆來源紀錄
- CR2P20023 · UniProt INTERACTION · 4 experiments
- EFEMP2O95967 · UniProt INTERACTION · 3 experiments
- GOLGA6L9A6NEM1 · UniProt INTERACTION · 3 experiments
- HCN1O60741 · UniProt INTERACTION · 7 experiments
- KRT31Q15323 · UniProt INTERACTION · 3 experiments
- KRTAP10-8P60410 · UniProt INTERACTION · 3 experiments
- PLEKHF2Q9H8W4 · UniProt INTERACTION · 3 experiments
- VSIG4Q9Y279-1 · UniProt INTERACTION · 5 experiments · 2 筆來源紀錄
- CFHR2P36980 · UniProt INTERACTION · 2 experiments · 2 筆來源紀錄
C3前驅物在補體尚未活化時會移除4個Arg殘基,形成以雙硫鍵連接的β與α鏈。C3b由C3b鏈與C3 β鏈構成,兩者亦以雙硫鍵相連。C3b與C4b、C2b可組成C5 convertase;alternative pathway 的C5 convertase則含CFB與C3b,並可與CFP共同作用而活化。C3相關片段另與CR1、CR2及CFH互作。懷孕期間,C3dg可能與AGT及PRG2前驅形式形成異源六聚體複合體。感染情境中,病毒糖蛋白C與C3b互作可抑制補體活化;金黃色葡萄球菌蛋白Sbi可阻止C3dg與CR2結合,Fib亦與C3互作。
疾病與遺傳關聯
C3缺乏症與影響C3的基因變異相關,可造成補體 classical pathway 缺陷;患者可能反覆發生嚴重化膿性感染,部分患者也會出現自體免疫相關表現。年齡相關黃斑部退化第9型及非典型溶血性尿毒症第5型則屬疾病易感性與C3基因變異相關的情形,並非來源所述的單一因果關係;後者的表現型也可能受其他基因修飾。此外,C3及其切割產物ASP濃度升高與肥胖、糖尿病及冠狀動脈心臟病相關;短期耐力訓練則與基線ASP降低及其後脂肪儲存減少相關。
Contextual Functional Evidence Matrix
矩陣以「功能主張」為列,以細胞情境、干預條件、量測結果與證據來源為欄,方便比較同一功能在不同條件下的支持情形。只有含情境與實驗資訊的紀錄會列入矩陣;一般功能註解另列於下方。
功能註解總覽 · 19 筆
| 功能面向 | 功能敘述 | 證據類型 | 可查核來源 |
|---|---|---|---|
| 功能 | C3是 classical、alternative、lectin 與 GZMK 補體途徑中非酵素性成分的前驅物;這些途徑由蛋白質級聯構成,促成吞噬與病原體分解,並傳遞可強化適應性免疫的訊號。 | 含實驗來源 | 證據與來源Precursor of non-enzymatic components of the classical, alternative, lectin and GZMK complement pathways, which consist in a cascade of proteins that leads to phagocytosis and breakdown of pathogens and signaling that strengthens the adaptive immune system PMID 12878586 ↗ · PMID 18204047 ↗ · PMID 28264884 ↗ · PMID 31507604 ↗ · PMID 39814882 ↗ · PMID 39914456 ↗ · PMID 624565 ↗ · PMID 6554279 ↗ |
| 功能 | C3經C3 convertase切割後產生C3b;C3b以硫酯鍵共價附著於病原體表面,標記抗原以利移除,也可連接細胞表面醣類或免疫聚集物。它與C4b及C2b,或在 alternative pathway 中與CFB,形成可切割並活化C5的C5 convertase。 | 含實驗來源 | 證據與來源Non-enzymatic component of C5 convertase. Generated following cleavage by C3 convertase, it covalently attaches to the surface of pathogens, where it acts as an opsonin that marks the surface of antigens for removal. Complement C3b binds covalently via its reactive thioester, to cell surface carbohydrates or immune aggregates. Together with complement C4b, it then recruits the serine protease complement C2b to form the C5 convertase, which cleaves and activate C5, the next component of the complement pathways. In the alternative complement pathway, recruits the serine protease CFB to form the C5 convertase that cleaves and activates C5 PMID 12878586 ↗ · PMID 18204047 ↗ · PMID 2387864 ↗ · PMID 28264884 ↗ · PMID 31507604 ↗ · PMID 3653927 ↗ · PMID 3897448 ↗ · PMID 624565 ↗ · PMID 6554279 ↗ · PMID 6903192 ↗ · PMID 833545 ↗ · PMID 8349625 ↗ |
| 功能 | C3 convertase切割C3後釋出的C3a可結合C3AR1,啟動G蛋白偶聯受體訊號,並促進受體磷酸化及ARRB2介導的內化與胞吞。C3a刺激肥大細胞、嗜鹼性白血球釋放發炎介質,也吸引巨噬細胞與嗜中性球至發炎組織,促進吞噬及活性氧化物生成。 | 含實驗來源 | 證據與來源Mediator of local inflammatory process released following cleavage by C3 convertase. Acts by binding to its receptor, C3AR1, activating G protein-coupled receptor signaling, promoting the phosphorylation, ARRB2-mediated internalization and endocytosis of C3AR1. C3a anaphylatoxin stimulates the activation of immune cells such as mast cells and basophilic leukocytes to release inflammation agents, such as cytokines, chemokines and histamine, which promote inflammation development. Also acts as potent chemoattractant for the migration of macrophages and neutrophils to the inflamed tissues, resulting in neutralization of the inflammatory triggers by multiple ways, such as phagocytosis and generation of reactive oxidants PMID 342601 ↗ · PMID 37169960 ↗ · PMID 37852260 ↗ · PMID 5778786 ↗ · PMID 6968751 ↗ · PMID 8702752 ↗ · PMID 23383423 ↗ |
| 功能 | ASP具有脂肪生成激素作用,可促進脂肪細胞合成三酸甘油酯與運輸葡萄糖,參與脂肪儲存及餐後三酸甘油酯清除;合成作用似乎涉及PLC、MAPK與AKT訊號。ASP結合C5AR2後可促進受體訊號及ARRB2介導的內化,但不像C3a具有促發炎活性。 | 含實驗來源 | 證據與來源Adipogenic hormone that stimulates triglyceride synthesis and glucose transport in adipocytes, regulating fat storage and playing a role in postprandial triglyceride clearance. Appears to stimulate triglyceride synthesis via activation of the PLC, MAPK and AKT signaling pathways. Acts by binding to its receptor, C5AR2, activating G protein-coupled receptor signaling, promoting the phosphorylation, ARRB2-mediated internalization and endocytosis of C5AR2. In contrast to C3a anaphylatoxin peptide, does not show pro-inflammatory activity PMID 10432298 ↗ · PMID 11773063 ↗ · PMID 12540846 ↗ · PMID 15833747 ↗ · PMID 16333141 ↗ · PMID 19615750 ↗ · PMID 2909530 ↗ · PMID 37852260 ↗ · PMID 8376604 ↗ · PMID 9059512 ↗ |
| 功能 | C3相關產物在慢性發炎情境中具有吸引嗜中性球的作用。 | 推論支持 | |
| 交互作用 | 在補體尚未活化時,C3前驅物會先移除4個Arg殘基,之後形成β鏈與α鏈,兩條鏈由雙硫鍵連接。 | 含實驗來源 | 證據與來源In absence of complement activation, the C3 precursor is first processed by the removal of 4 Arg residues, forming two chains, beta and alpha, linked by a disulfide bond PMID 7240134 ↗ |
| 交互作用 | C3b由C3b與C3 β鏈以雙硫鍵連接。C3b可與C4b及絲胺酸蛋白酶C2b組成C5 convertase;alternative pathway 的C5 convertase則由CFB與C3b構成。C3b也與CFP、CR1及CFH互作,並參與補體複合體形成或調節。 | 含實驗來源 | 證據與來源Complement C3b is composed of complement C3b and complement C3 beta chains that are associated via disulfide bonds. Non-enzymatic component of the C5 convertase, also named C4bC2bC3b, composed of the serine protease complement C2b (C2), complement C3b, as well as complement C4b (C4). Non-enzymatic component of the C5 convertase of the alternative complement pathways composed of the serine protease complement CFB and complement C3b. Interacts with CFP; interaction takes place together with CFB in the alternative complement system and allows the complex to become active. Interacts with CR1 (via Sushi 8 and Sushi 9 domains). Interacts with CFH PMID 12878586 ↗ · PMID 17051150 ↗ · PMID 1740458 ↗ · PMID 18204047 ↗ · PMID 21285368 ↗ · PMID 2387864 ↗ · PMID 28264884 ↗ · PMID 28671664 ↗ · PMID 2972794 ↗ · PMID 30643019 ↗ · PMID 31507604 ↗ · PMID 3638964 ↗ · PMID 624565 ↗ · PMID 6554279 ↗ · PMID 6919543 ↗ · PMID 8175757 ↗ · PMID 9748277 ↗ |
| 交互作用 | C3與補體因子CFH及CR2有互作記錄;此項敘述未提供其他互作情境或作用結果。 | 含實驗來源 | |
| 交互作用 | 懷孕期間,C3dg會與AGT及PRG2前驅形式形成複合體,該複合體可能為2:2:2異源六聚體。C3dg另透過N端Sushi domains 1與2和CR2互作。 | 含實驗來源 | 證據與來源During pregnancy, C3dg exists as a complex (probably a 2:2:2 heterohexamer) with AGT and the proform of PRG2. Interacts with CR2 (via the N-terminal Sushi domains 1 and 2) PMID 11387479 ↗ · PMID 20083651 ↗ · PMID 21527715 ↗ · PMID 7539791 ↗ |
| 交互作用 | 在微生物感染情境中,C3b會與herpes simplex virus 1(HHV-1)及herpes simplex virus 2(HHV-2)的包膜糖蛋白C互作;此互作會抑制補體系統活化。 | 含實驗來源 | 證據與來源(Microbial infection) C3b interacts with herpes simplex virus 1 (HHV-1) and herpes simplex virus 2 (HHV-2) envelope glycoprotein C; this interaction inhibits the activation of the complement system PMID 2849025 ↗ |
| 交互作用 | 在微生物感染情境中,C3與金黃色葡萄球菌(Staphylococcus aureus)的免疫球蛋白結合蛋白Sbi互作;這項互作會阻止C3dg與CR2結合。 | 含實驗來源 | 證據與來源(Microbial infection) Interacts with Staphylococcus aureus immunoglobulin-binding protein Sbi; this interaction prevents the association between C3dg and CR2 PMID 19112495 ↗ · PMID 20083651 ↗ · PMID 21055811 ↗ |
| 交互作用 | 在微生物感染情境中,C3與金黃色葡萄球菌(Staphylococcus aureus)蛋白Fib互作;此項敘述未提供互作後的作用結果。 | 含實驗來源 | |
| 細胞定位 | Secreted | 含實驗來源 | |
| 細胞定位 | 分泌的C3b可位於細胞表面並共價附著於病原體表面;其內部硫酯鍵與標的表面的醣類抗原反應,形成醯胺鍵或酯鍵。 | 含實驗來源 | 證據與來源Complement C3b; Secreted; Cell surface; Covalently associated with the surface of pathogens: the internal thioester bond reacts with carbohydrate antigens on the target surface to form amide or ester bonds PMID 3653927 ↗ · PMID 3897448 ↗ · PMID 6903192 ↗ · PMID 833545 ↗ · PMID 8349625 ↗ |
| 細胞定位 | C3a anaphylatoxin具有分泌定位註記。 | 含實驗來源 | |
| 疾病關聯 | C3缺乏症是罕見的補體 classical pathway 缺陷,與影響C3基因的變異相關。患者可能反覆發生嚴重化膿性感染,原因與病原體調理作用不足有關;部分患者也可能有關節痛、血管炎性皮疹、類狼瘡症候群或膜增生性腎小球腎炎等自體免疫表現。 | 含實驗來源 | 證據與來源Complement component 3 deficiency C3D A rare defect of the complement classical pathway. Patients develop recurrent, severe, pyogenic infections because of ineffective opsonization of pathogens. Some patients may also develop autoimmune disorders, such as arthralgia and vasculitic rashes, lupus-like syndrome and membranoproliferative glomerulonephritis. The disease is caused by variants affecting the gene represented in this entry MIM: 613779 PMID 7961791 ↗ |
| 疾病關聯 | 年齡相關黃斑部退化第9型是一種多因子眼疾,疾病易感性與影響C3基因的變異相關。多數患者可見視網膜色素上皮下、Bruch膜內的黃色蛋白質與脂質堆積;來源未指出C3變異單獨造成此病。 | 含實驗來源 | 證據與來源Macular degeneration, age-related, 9 ARMD9 A form of age-related macular degeneration, a multifactorial eye disease and the most common cause of irreversible vision loss in the developed world. In most patients, the disease is manifest as ophthalmoscopically visible yellowish accumulations of protein and lipid that lie beneath the retinal pigment epithelium and within an elastin-containing structure known as Bruch membrane. Disease susceptibility is associated with variants affecting the gene represented in this entry MIM: 611378 PMID 17634448 ↗ · PMID 24036952 ↗ |
| 疾病關聯 | 非典型溶血性尿毒症第5型是複雜遺傳疾病,疾病易感性與影響C3基因的變異相關,其他基因也可能修飾表現型。其特徵包括微血管病性溶血性貧血、血小板減少及腎衰竭,且沒有腸胃炎與腹瀉發作;相較典型型態,預後較差。 | 含實驗來源 | 證據與來源Hemolytic uremic syndrome, atypical, 5 AHUS5 An atypical form of hemolytic uremic syndrome. It is a complex genetic disease characterized by microangiopathic hemolytic anemia, thrombocytopenia, renal failure and absence of episodes of enterocolitis and diarrhea. In contrast to typical hemolytic uremic syndrome, atypical forms have a poorer prognosis, with higher death rates and frequent progression to end-stage renal disease. Disease susceptibility is associated with variants affecting the gene represented in this entry. Other genes may play a role in modifying the phenotype MIM: 612925 PMID 18796626 ↗ · PMID 20513133 ↗ |
| 疾病關聯 | C3及其切割產物ASP濃度升高與肥胖、糖尿病及冠狀動脈心臟病相關。短期耐力訓練會降低基線ASP濃度,隨後脂肪儲存也減少。 | 資料庫紀錄 | 證據與來源Increased levels of C3 and its cleavage product ASP, are associated with obesity, diabetes and coronary heart disease. Short-term endurance training reduces baseline ASP levels and subsequently fat storage |
核酸與蛋白質序列
ACTCCTCCCCATCCTCTCCCTCTGTCCCTCTGTCCCTCTG40ACCCTGCACTGTCCCAGCACCATGGGACCCACCTCAGGTC80CCAGCCTGCTGCTCCTGCTACTAACCCACCTCCCCCTGGC120TCTGGGGAGTCCCATGTACTCTATCATCACCCCCAACATC160TTGCGGCTGGAGAGCGAGGAGACCATGGTGCTGGAGGCCC200ACGACGCGCAAGGGGATGTTCCAGTCACTGTTACTGTCCA240CGACTTCCCAGGCAAAAAACTAGTGCTGTCCAGTGAGAAG280ACTGTGCTGACCCCTGCCACCAACCACATGGGCAACGTCA320CCTTCACGATCCCAGCCAACAGGGAGTTCAAGTCAGAAAA360GGGGCGCAACAAGTTCGTGACCGTGCAGGCCACCTTCGGG400ACCCAAGTGGTGGAGAAGGTGGTGCTGGTCAGCCTGCAGA440GCGGGTACCTCTTCATCCAGACAGACAAGACCATCTACAC480CCCTGGCTCCACAGTTCTCTATCGGATCTTCACCGTCAAC520CACAAGCTGCTACCCGTGGGCCGGACGGTCATGGTCAACA560TTGAGAACCCGGAAGGCATCCCGGTCAAGCAGGACTCCTT600GTCTTCTCAGAACCAGCTTGGCGTCTTGCCCTTGTCTTGG640GACATTCCGGAACTCGTCAACATGGGCCAGTGGAAGATCC680GAGCCTACTATGAAAACTCACCACAGCAGGTCTTCTCCAC720TGAGTTTGAGGTGAAGGAGTACGTGCTGCCCAGTTTCGAG760GTCATAGTGGAGCCTACAGAGAAATTCTACTACATCTATA800ACGAGAAGGGCCTGGAGGTCACCATCACCGCCAGGTTCCT840CTACGGGAAGAAAGTGGAGGGAACTGCCTTTGTCATCTTC880GGGATCCAGGATGGCGAACAGAGGATTTCCCTGCCTGAAT920CCCTCAAGCGCATTCCGATTGAGGATGGCTCGGGGGAGGT960cDNA 使用 DNA 字母 T;mRNA 模式改以 U 顯示。轉錄本保留已註解的非編碼區,未另外加入 poly(A) 尾;非編碼 RNA 的參考轉錄本也可能仍需後續加工。數字為所選序列的 1-based 位置。長序列以黃色捲軸瀏覽,可複製或下載完整轉錄本與蛋白質;基因組 DNA 隨捲動取得所需範圍。